Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, March 11, 2019 at 4:00 PM to 4:30 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?


Currently submitted to: JMIR mHealth and uHealth

Date Submitted: Jun 19, 2019
Open Peer Review Period: Jun 19, 2019 - Jun 27, 2019
(closed for review but you can still tweet)

NOTE: This is an unreviewed Preprint

Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note “no longer under consideration” will appear above).

Peer-review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a “Peer-Review Me” button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.

Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

Final version: If our system detects a final peer-reviewed “version of record” (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.

Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.

Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.

Development and Use of a Mobile Texting App ‘Heptalk’: Its Efficacy in Patient Engagement in Viral Hepatitis B Care

  • Chul Hyun; 
  • Joseph McMenamin; 
  • Okhyun Ko; 
  • Soonsik Kim; 



Chronic hepatitis B virus (HBV) infection is a major cause of liver-related morbidity and mortality among Asian Americans in the U.S. population. Despite the available resources, a majority of HBV infected individuals are not able to access adequate health care owing to numerous barriers.


This study was designed to assess the efficacy of a newly developed mobile texting app ‘heptalk’ to overcome these barriers and to help engage HBV infected and non-immune individuals to health access.


A mobile texting app heptalk was employed for a two-way communication between patients and patient navigators (PNs). A total of 82 Korean-American participants who were either HBV infected or non-immune to HBV were enrolled for the study. After informed consent was obtained, both the frequency and themes of the texting messages were evaluated. The effects of these communications on the linkage to care (LTC) at the end of the six-month intervention period were analyzed and discussed.


On average, PNs sent and received 14 and 8 messages per participant, respectively, during the six-month period. The themes of the messages were similar with respect to the following four categories: finding providers, scheduling appointments with providers, health education, and financial issues. Of 82 participants, a total of 78 were linked to care within six months, a 95 % linkage rate.


A mobile texting app heptalk may be employed as an effective and strategic tool to facilitate communicative interaction between patients and PNs or healthcare providers (HCPs), thereby improving patient engagement and healthcare access.


Please cite as:

Hyun C, McMenamin J, Ko O, Kim S

Development and Use of a Mobile Texting App ‘Heptalk’: Its Efficacy in Patient Engagement in Viral Hepatitis B Care

JMIR Preprints. 19/06/2019:15098

DOI: 10.2196/preprints.15098


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.